엔케이젠바이오텍코리아

182400KOSDAQ기초 의약물질 제조업

40.9 / 100

Reference Date: 2026-04-13

Financial Score14.0 / 40

News Sentiment6.9 / 25

Momentum10.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, Revenue is on a declining trend. Roughly flat over the past month, and news sentiment is negative.

Company InformationBased on 2025 Annual Report

Business Overview

Enkmax BioTech Korea focuses on immunotherapy, immunodiagnostic kits, health supplement sales, and bio research reagents. The company utilizes its 'SuperNK' platform technology, based on NK cells, to develop immunotherapy treatments for various diseases, with global clinical trials underway. Its immunodiagnostic kits, the world's first to measure NK cell activity in whole blood, hold patents in 30 countries, and health supplements like NK365, which enhance immunity, are also a key product line.

Number of Employees

70people

Average Salary

0.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 33.454.0Point

PBR

—Industry Average 2.033.5Point

ROE

—Industry Average -4.293.5Point

Debt Ratio

57.01Industry Average 6.610.0Point

8.6x industry avg (risky)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼11.1% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲65.8% (2-year basis)

ROE Trend

0.0 / 4

Detailed News Sentiment

4 totalPositive 0Neutral 1Negative 2Average Sentiment Score 20

Neutral
‘동전주 퇴출’ 앞두고 무상감자 급증… 주식병합 통한 주가 부양 ‘.....
금융 당국의 동전주 퇴출 의지 이후 코스닥 상장사들의 무상감자가 급증하고 있다는 업계 전반에 대한 뉴스이다.
Negative
엔케이젠바이오 前 임원, 내부정보로 5.5억 부당이득
엔케이젠바이오텍코리아의 전 IR 담당 임원이 세포 치료제 호재성 정보를 이용해 5억원이 넘는 부당 이득을 챙겨 검찰에 고발되었다는 뉴스이다.
Negative
‘치료제 호재’ 미리 알고 주식매매 5.5억 챙겨…바이오 기업 前 임원...
엔케이젠바이오텍코리아의 전 임원이 자회사의 면역세포 치료제 관련 미공개 호재성 정보를 이용해 5억 원이 넘는 부당이득을 챙겨 검찰에 고발되었다는 뉴스이다.

Detailed Momentum

52-week position4.0Point

52w mid range (50%)

Current 3,670Won52-week high 3,67052-week low 3,670

1-month return3.0Point

1m 0% (flat)

Volume trend3.0Point

Volume flat

Detailed Disclosure

10 totalPositive 0Neutral 10Negative 0

Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-31
Neutral정기주주총회결과2026-03-31
Neutral[기재정정]사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-31
Neutral사업보고서 (2025.12)2026-03-24
Neutral[기재정정]사업보고서 (2025.12)2026-03-24